Data gathered: November 30
Alternative Data for Cassava Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 98,000 | Sign up | Sign up | Sign up |
| Google Trends | 8 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 11 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 60 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 55,106 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 37 | Sign up | Sign up | Sign up |
About Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
| Price | $3.84 |
| Target Price | Sign up |
| Volume | 15,790,000 |
| Market Cap | $191M |
| Year Range | $3.83 - $35.08 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MoreNovember 29 - Yahoo |
 |
Cassava Sciences (NASDAQ:SAVA) Downgraded to Neutral Rating by HC WainwrightNovember 27 - ETF Daily News |
 |
Cassava Sciences: Probably The End Of The SagaNovember 26 - SeekingAlpha |
 |
A Post-Mortem on Cassava SciencesNovember 26 - Yahoo |
 |
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage StudyNovember 26 - Yahoo |
 |
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The CoffinNovember 25 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 13M | -13M | -28M | -31M | -0.580 |
| Q2 '24 | 0 | 46M | -46M | 6.2M | -61M | 0.130 |
| Q1 '24 | 0 | 3.8M | -3.8M | 25M | -20M | 0.580 |
| Q4 '23 | 2.3M | 4.1M | -4.1M | -21M | -23M | -0.500 |
| Q3 '23 | 0 | 4.4M | -4.4M | -26M | -28M | -0.610 |
Insider Transactions View All
| ROBERTSON SANFORD filed to buy 886,851 shares at $17.5. August 24 '23 |
| Barry Richard filed to buy 293,477 shares at $16.7. August 23 '23 |
| Barry Richard filed to buy 276,906 shares at $16.8. August 23 '23 |
| Barry Richard filed to buy 275,000 shares at $25.8. March 8 '23 |
| Barry Richard filed to buy 197,724 shares at $26.1. March 8 '23 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Christopher Jacobs Republican |
Jan 20, 23 | Buy | $1K - $15K |
| Christopher Jacobs Republican |
Dec 12, 22 | Sell | $1K - $15K |
Read more about Cassava Sciences (SAVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cassava Sciences?
The Market Cap of Cassava Sciences is $191M.
What is the current stock price of Cassava Sciences?
Currently, the price of one share of Cassava Sciences stock is $3.84.
How can I analyze the SAVA stock price chart for investment decisions?
The SAVA stock price chart above provides a comprehensive visual representation of Cassava Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cassava Sciences shares. Our platform offers an up-to-date SAVA stock price chart, along with technical data analysis and alternative data insights.
Does SAVA offer dividends to its shareholders?
As of our latest update, Cassava Sciences (SAVA) does not offer dividends to its shareholders. Investors interested in Cassava Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cassava Sciences?
Some of the similar stocks of Cassava Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.